Comparing SG&A Expenses: Blueprint Medicines Corporation vs Corcept Therapeutics Incorporated Trends and Insights

Biotech Giants: SG&A Expense Trends from 2014 to 2023

__timestampBlueprint Medicines CorporationCorcept Therapeutics Incorporated
Wednesday, January 1, 2014789000034916000
Thursday, January 1, 20151445600036949000
Friday, January 1, 20161921800045240000
Sunday, January 1, 20172798600062416000
Monday, January 1, 20184792800081289000
Tuesday, January 1, 201996388000100359000
Wednesday, January 1, 2020157743000105326000
Friday, January 1, 2021195293000122356000
Saturday, January 1, 2022237374000152848000
Sunday, January 1, 2023295141000184259000
Monday, January 1, 2024359272000
Loading chart...

Unleashing insights

SG&A Expenses: A Tale of Two Biotech Companies

In the competitive world of biotechnology, managing expenses is crucial for sustainable growth. This analysis compares the Selling, General, and Administrative (SG&A) expenses of Blueprint Medicines Corporation and Corcept Therapeutics Incorporated from 2014 to 2023. Over this period, Blueprint Medicines saw a staggering increase of over 3,600% in SG&A expenses, reflecting its aggressive expansion and investment in operational infrastructure. In contrast, Corcept Therapeutics experienced a more modest rise of approximately 430%, indicating a steady but cautious growth strategy.

By 2023, Blueprint Medicines' SG&A expenses were nearly 60% higher than Corcept's, highlighting its commitment to scaling operations. This trend underscores the differing strategic priorities of these companies, with Blueprint focusing on rapid growth and Corcept maintaining a balanced approach. Investors and industry analysts should consider these trends when evaluating the financial health and strategic direction of these biotech firms.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025